1. Home
  2. FINS vs LIMNW Comparison

FINS vs LIMNW Comparison

Compare FINS & LIMNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FINS
  • LIMNW
  • Stock Information
  • Founded
  • FINS 2019
  • LIMNW N/A
  • Country
  • FINS United States
  • LIMNW United States
  • Employees
  • FINS N/A
  • LIMNW N/A
  • Industry
  • FINS Finance/Investors Services
  • LIMNW
  • Sector
  • FINS Finance
  • LIMNW
  • Exchange
  • FINS Nasdaq
  • LIMNW Nasdaq
  • Market Cap
  • FINS N/A
  • LIMNW N/A
  • IPO Year
  • FINS N/A
  • LIMNW N/A
  • Fundamental
  • Price
  • FINS $12.91
  • LIMNW $0.38
  • Analyst Decision
  • FINS
  • LIMNW
  • Analyst Count
  • FINS 0
  • LIMNW 0
  • Target Price
  • FINS N/A
  • LIMNW N/A
  • AVG Volume (30 Days)
  • FINS 78.0K
  • LIMNW N/A
  • Earning Date
  • FINS 01-01-0001
  • LIMNW N/A
  • Dividend Yield
  • FINS 9.97%
  • LIMNW N/A
  • EPS Growth
  • FINS N/A
  • LIMNW N/A
  • EPS
  • FINS N/A
  • LIMNW N/A
  • Revenue
  • FINS N/A
  • LIMNW N/A
  • Revenue This Year
  • FINS N/A
  • LIMNW N/A
  • Revenue Next Year
  • FINS N/A
  • LIMNW N/A
  • P/E Ratio
  • FINS N/A
  • LIMNW N/A
  • Revenue Growth
  • FINS N/A
  • LIMNW N/A
  • 52 Week Low
  • FINS $11.61
  • LIMNW N/A
  • 52 Week High
  • FINS $12.57
  • LIMNW N/A
  • Technical
  • Relative Strength Index (RSI)
  • FINS 40.34
  • LIMNW N/A
  • Support Level
  • FINS $12.76
  • LIMNW N/A
  • Resistance Level
  • FINS $13.21
  • LIMNW N/A
  • Average True Range (ATR)
  • FINS 0.12
  • LIMNW 0.00
  • MACD
  • FINS -0.03
  • LIMNW 0.00
  • Stochastic Oscillator
  • FINS 22.35
  • LIMNW 0.00

About LIMNW Liminatus Pharma Inc. Warrants

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

Share on Social Networks: